Combining multi-omics and drug perturbation profiles to identify novel treatments that improve disease phenotypes in spinal muscular atrophy [preprint]
Meijboom, Katharina E Volpato, Viola Monzón-Sandoval, Jimena Hoolachan, Joseph M. Hammond, Suzan M. Abendroth, Frank de Jong, Olivier Gerrit Hazell, Gareth Ahlskog, Nina Wood, Matthew J.A.
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the lead candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including SMN expression and lifespan. Our work highlights the potential of multiple, parallel data driven approaches for development of novel treatments for use in combination with SMN restoration therapies.
Source
bioRxiv 2019.12.17.879353; doi: https://doi.org/10.1101/2019.12.17.879353. Link to preprint on bioRxiv service.